Brivaracetam, a novel oral antiepileptic drug with a high affinity for synaptic vesicle protein 2A (SV2A), was approved in Europe and the US as an adjunctive therapy for the treatment of partial onset seizures with or without secondary generalization in patients aged 16 or older.
- Additional information
Brivaracetam CAS 357336-20-0 Product Information
|Synonyms:||(alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;UCB-34714;1-PyrrolidineacetaMide, α-ethyl-2-oxo-4-propyl-, (αS,4R)-;(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanaMide;2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide;(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide;API-Anti Epilepsy;brivaracetam|
|Boiling Point:||409.3±28.0 °C at 760 mmHg|
|Appearance:||White to Off-White Solid|
|Applications:||Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. It provides a new monotherapy treatment option for epilepsy patients 16 years of age and older who suffering partial-onset[focal] seizures, which can be initiated at a therapeutic dose at day one.|
|Solubility:||DMSO (Slightly), Methanol (Slightly)|
Brivaracetam is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs.
brivaracetam loading dose/brivaracetam dose
1 month to 16 years:
Weight: Less than 11 kg: Initial dose: 0.75 to 1.5 mg/kg orally twice a day; Maintenance dose: 0.75 to 3 mg/kg orally twice a day
Weight: 11 kg to less than 20 kg: Initial dose: 0.5 to 1.25 mg/kg orally twice a day; Maintenance dose: 0.5 to 2.5 mg/kg orally twice a day
Weight: 20 kg to less than 50 kg: Initial dose: 0.5 to 1 mg/kg orally twice a day; Maintenance dose: 0.5 to 2 mg/kg orally twice a day
Weight: 50 kg or greater: Initial dose: 25 to 50 mg orally twice a day; Maintenance dose: 25 to 100 mg orally twice a day
16 years of age and older:
Initial dose: 50 mg orally 2 times a day
Maintenance dose: 25 mg to 100 mg orally twice a day
brivaracetam half life
Brivaracetam exhibits linear pharmacokinetics over a wide dose range, is rapidly and completely absorbed after oral administration, has an elimination half-life of seven to eight hours.
- When initiating therapy, gradual dose escalation is not required; following initiation, dose should be adjusted based on clinical response and tolerability.
- Tablets, oral solution and injection can be used interchangeably.
brivaracetam mechanism of action/how does brivaracetam work
Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A), like levetiracetam. but with 20-fold greater affinity. There is some evidence that racetams including levetiracetam and brivaracetam access the luminal side of recycling synaptic vesicles during vesicular endocytosis. They may reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity, such as is believed to occur during epileptic activity.
brivaracetam vs levetiracetam/brivaracetam and leviracetam
Brivaracetam (BRV) is an AED in the racetam group which was discovered as an analog to the related racetam drug levetiracetam (LEV). Both drugs have a similar mechanism of action with a selective and high affinity for binding to synaptic vesicle protein 2A, but they may differ in their pharmacological profiles.
brivaracetam side effects
The most common adverse effects include sleepiness, dizziness, nausea and vomiting. More rarely, coordination problems and changes in behaviour (such as severe depression, aggression, hostility, impatience, rage, depression, suicide ideology, etc.) can occur.
DMSO (Slightly), Methanol (Slightly)
There are no reviews yet.